ZIOP ZIOPHARM Oncology Inc.

Ziopharm Oncology to Participate in Jefferies Cell Therapy Virtual Summit on October 5, 2020

Ziopharm Oncology to Participate in Jefferies Cell Therapy Virtual Summit on October 5, 2020
EN
01/10/2020

Underlying

ZIOPZIOPHARM Oncology Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZIOPHARM Oncology Inc.

 PRESS RELEASE
Free
ZIOP ZIOPHARM Oncolo...

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”) today announced that it has entered into a definitive agreement with certain investors (the “SPA”) for the purchase and sale of an aggregate of 610,399 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.36 per share (or pre-funded warrant in lieu thereof) in a registered direct offering (the “Offering”) on June 20, 2025 based on the 5-day average Nasdaq official closing price. The...

June 23, 2025 1 EN
 PRESS RELEASE
Free
ZIOP ZIOPHARM Oncolo...

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, P...

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53Company continues to explore potential strategic alternatives; cost-savings measures expected to extend cash runaway into the second quar...

November 14, 2023 1 EN
 PRESS RELEASE
Free
ZIOP ZIOPHARM Oncolo...

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, ...

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patientsCompany to wind down TCR-T Library Phase 1/2 trial and concurrently explore potential partnering opportunities for the hunTR® platform as well as broad strategic alternativesReducing headcount by approximately 60% while retaining key hunTR® R&D capabilities HOUS...

August 14, 2023 1 EN
 PRESS RELEASE
Free
ZIOP ZIOPHARM Oncolo...

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global S...

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Company will present at the 2nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 – July 1, 2023. Alaunos Director of Translational Sciences Matthew Collinson-Pautz, Ph.D., will discuss the Company’s TCR-T therapy...

June 29, 2023 1 EN
 PRESS RELEASE
Free
ZIOP ZIOPHARM Oncolo...

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/...

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indicationsTreatment was well tolerated with a manageable safety profile and persistence of TCR-T cells in peripheral blood observed in all three treated patients at last follow-upProof-of-concept demonstrated for non-viral Sleeping Beauty cell engineering platform in effective manufa...

May 25, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch